Form 4: Vistagen Therapeutics Director Acquires Stock Options
SEC Form 4 Filing
Director Ann Michelle Cunningham acquired 14,100 stock options in Vistagen Therapeutics on September 6, 2024.
Summary
- On September 6, 2024, Ann Michelle Cunningham, a director of Vistagen Therapeutics, acquired 14,100 stock options.
- The options have an exercise price of $3.25.
- 25% of the options vest immediately, with the remaining vesting in equal monthly installments over the next year.
- The options expire on September 6, 2034.
Sentiment
Score: 5
Explanation: This is a routine filing related to stock option grants, so the sentiment is neutral.
Industry Context
This is a standard Form 4 filing, indicating a change in beneficial ownership by a company insider. It's common for directors and officers to receive stock options as part of their compensation.
Stakeholder Impact
- The granting of stock options to a director could be seen as a positive sign by shareholders, aligning the director's interests with those of the shareholders.
Key Dates
| Date | Description |
|---|---|
| 09/06/2024 | Date of the transaction: Ann Michelle Cunningham acquired 14,100 stock options. |
| 09/06/2034 | Expiration date of the stock options. |
| 09/10/2024 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.